Your browser doesn't support javascript.
loading
Treatment efficacy of ribociclib or palbociclib plus letrozole in hormone receptor-positive/HER2-negative metastatic breast cancer.
Kahraman, Seda; Erul, Enes; Seyyar, Mustafa; Gumusay, Ozge; Bayram, Ertugrul; Demirel, Burcin Cakan; Acar, Omer; Aksoy, Sercan; Baytemur, Naziyet Kose; Sahin, Elif; Cabuk, Devrim; Basaran, Gul; Paydas, Semra; Yaren, Arzu; Guven, Deniz Can; Erdogan, Atike Pinar; Demirci, Umut; Yasar, Alper; Bayoglu, Ibrahim Vedat; Hizal, Mutlu; Gulbagci, Burcu; Paksoy, Nail; Davarci, Sena Ece; Yilmaz, Funda; Dogan, Ozlem; Orhan, Sibel Oyucu; Kayikcioglu, Erkan; Aytac, Ali; Keskinkilic, Merve; Mocan, Eda Eylemer; Unal, Olcun Umit; Aydin, Esra; Yucel, Hakan; Isik, Deniz; Eren, Onder; Uluc, Basak Oyan; Ozcelik, Melike; Hacibekiroglu, Ilhan; Aydiner, Adnan; Demir, Hacer; Oksuzoglu, Berna; Cilbir, Ebru; Cubukcu, Erdem; Cetin, Bulent; Oktay, Esin; Erol, Cihan; Okutur, Sadi Kerem; Yildirim, Nilgun; Alkan, Ali; Selcukbiricik, Fatih.
Afiliação
  • Kahraman S; Department of Medical Oncology, Ankara Yildirim Beyazit University, Ankara City Hospital, Ankara, 06800, Turkey.
  • Erul E; Department of Medical Oncology, Hacettepe University Cancer Institute, Ankara, 06590, Turkey.
  • Seyyar M; Department of Medical Oncology, Kocaeli University Medical Faculty Hospital, Kocaeli, 41000, Turkey.
  • Gumusay O; Department of Medical Oncology, Acibadem University, School of Medicine, Istanbul, 34750, Turkey.
  • Bayram E; Department of Medical Oncology, Cukurova University, Adana, 01330, Turkey.
  • Demirel BC; Department of Medical Oncology, Pamukkale University Hospital, Denizli, 20160, Turkey.
  • Acar O; Department of Medical Oncology, Manisa Celal Bayar University Hospital, Mersin, 45120, Turkey.
  • Aksoy S; Department of Medical Oncology, Hacettepe University Cancer Institute, Ankara, 06590, Turkey.
  • Baytemur NK; Department of Medical Oncology, Ankara Memorial Hospital, Ankara, 06520, Turkey.
  • Sahin E; Department of Medical Oncology, Kocaeli University Medical Faculty Hospital, Kocaeli, 41000, Turkey.
  • Cabuk D; Department of Medical Oncology, Kocaeli University Medical Faculty Hospital, Kocaeli, 41000, Turkey.
  • Basaran G; Department of Medical Oncology, Acibadem University, School of Medicine, Istanbul, 34750, Turkey.
  • Paydas S; Department of Medical Oncology, Cukurova University, Adana, 01330, Turkey.
  • Yaren A; Department of Medical Oncology, Pamukkale University Hospital, Denizli, 20160, Turkey.
  • Guven DC; Department of Medical Oncology, Hacettepe University Cancer Institute, Ankara, 06590, Turkey.
  • Erdogan AP; Department of Medical Oncology, Manisa Celal Bayar University Hospital, Mersin, 45120, Turkey.
  • Demirci U; Department of Medical Oncology, Ankara Memorial Hospital, Ankara, 06520, Turkey.
  • Yasar A; Department of Medical Oncology, Marmara University Pendik Research & Application Hospital, Istanbul, 34899, Turkey.
  • Bayoglu IV; Department of Medical Oncology, Marmara University Pendik Research & Application Hospital, Istanbul, 34899, Turkey.
  • Hizal M; Department of Medical Oncology, Ankara Yildirim Beyazit University, Ankara City Hospital, Ankara, 06800, Turkey.
  • Gulbagci B; Department of Medical Oncology, Sakarya University School of Medicine, Sakarya, 54187, Turkey.
  • Paksoy N; Department of Medical Oncology, Istanbul University, Istanbul, 34093, Turkey.
  • Davarci SE; Department of Medical Oncology, Afyonkarahisar Health Sciences University, Afyonkarahisar, 03200, Turkey.
  • Yilmaz F; Department of Medical Oncology, Dr. Abdurrahman Yurtaslan Ankara Oncology Training & Research Hospital, Ankara, 06200, Turkey.
  • Dogan O; Department of Medical Oncology, Ankara Etlik City Hospital, Ankara, 06170, Turkey.
  • Orhan SO; Department of Medical Oncology, Uludag University, Bursa, 16059, Turkey.
  • Kayikcioglu E; Department of Medical Oncology, Suleyman Demirel University, Isparta, 32260, Turkey.
  • Aytac A; Department of Medical Oncology, Aydin Adnan Menderes University Training & Research Hospital, Aydin, 09100, Turkey.
  • Keskinkilic M; Department of Medical Oncology, Dokuz Eylül University Research & Application Hospital, Izmir, 35340, Turkey.
  • Mocan EE; Department Of Medical Oncology, Ankara University, Ankara, 06080, Turkey.
  • Unal OU; Department of Medical Oncology, Tepecik Training & Research Hospital, Izmir, 35180, Turkey.
  • Aydin E; Department of Medical Oncology, Recep Tayyip Erdogan University Training & Research Hospital, Rize, 53020, Turkey.
  • Yucel H; Department of Medical Oncology, Gaziantep University, Gaziantep, 27580, Turkey.
  • Isik D; Department of Medical Oncology, Kocaeli Medical Park Hospital, Kocaeli, 41140, Turkey.
  • Eren O; Department of Medical Oncology, Selcuk University Medical Faculty Hospital, Konya, 42250, Turkey.
  • Uluc BO; Department of Medical Oncology, Acibadem University, School of Medicine, Istanbul, 34750, Turkey.
  • Ozcelik M; Department of Medical Oncology, Umraniye Training & Research Hospital, Istanbul, 34764, Turkey.
  • Hacibekiroglu I; Department of Medical Oncology, Sakarya University School of Medicine, Sakarya, 54187, Turkey.
  • Aydiner A; Department of Medical Oncology, Istanbul University, Istanbul, 34093, Turkey.
  • Demir H; Department of Medical Oncology, Afyonkarahisar Health Sciences University, Afyonkarahisar, 03200, Turkey.
  • Oksuzoglu B; Department of Medical Oncology, Dr. Abdurrahman Yurtaslan Ankara Oncology Training & Research Hospital, Ankara, 06200, Turkey.
  • Cilbir E; Department of Medical Oncology, Ankara Etlik City Hospital, Ankara, 06170, Turkey.
  • Cubukcu E; Department of Medical Oncology, Uludag University, Bursa, 16059, Turkey.
  • Cetin B; Department of Medical Oncology, Suleyman Demirel University, Isparta, 32260, Turkey.
  • Oktay E; Department of Medical Oncology, Aydin Adnan Menderes University Training & Research Hospital, Aydin, 09100, Turkey.
  • Erol C; Department of Medical Oncology, Ankara Yildirim Beyazit University, Ankara City Hospital, Ankara, 06800, Turkey.
  • Okutur SK; Department of Medical Oncology, Istanbul Arel University, Bahcelievler Memorial Hospital, Istanbul, 34537, Turkey.
  • Yildirim N; Department of Medical Oncology, Firat University Hospital, Elazig, 23200, Turkey.
  • Alkan A; Department of Medical Oncology, Mugla Sitki Koçman University Training & Research Hospital, Mugla, 48000, Turkey.
  • Selcukbiricik F; Department of Medical Oncology, Koç University Hospital, Istanbul, 34010, Turkey.
Future Oncol ; 19(10): 727-736, 2023 Mar.
Article em En | MEDLINE | ID: mdl-37133230
ABSTRACT

Background:

Ribociclib, palbociclib and abemaciclib are currently approved CDK4/6 inhibitors along with aromatase inhibitors as the first-line standard-of-care for patients with hormone receptor-positive, HER2-negative metastatic breast cancer.

Methods:

The authors report retrospective real-life data for 600 patients with estrogen receptor- and/or progesterone receptor-positive and HER2-negative metastatic breast cancer who were treated with ribociclib and palbociclib in combination with letrozole. Results &

conclusion:

The results demonstrated that the combination of palbociclib or ribociclib with letrozole has similar progression-free survival and overall survival benefit in real life for the patient group with similar clinical features. Specifically, endocrine sensitivity may be a factor to be considered in the treatment preference.
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias da Mama Idioma: En Ano de publicação: 2023 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias da Mama Idioma: En Ano de publicação: 2023 Tipo de documento: Article